AIO-Studien-gGmbH

aio-portal.de

Total trials

59

Active

6

Phase 3

6

Total enrollment

23,475

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Atezolizumab2
Maximum tolerated dose, MTD: D,L-methadone hydrochloride1
IMM-1011
Osimertinib1

Next readouts

  • 2025-12
  • 2026-03
  • 2027-04

Top conditions

  • Metastatic Colorectal Cancer3
  • Colorectal Neoplasms3
  • Esophageal Cancer2
  • GastroEsophageal Cancer2
  • Biliary Tract Cancer2
  • Metastatic Pancreatic Cancer2
  • Colorectal Cancer2
  • Ductal Adenocarcinoma of the Pancreas2

Frequently asked questions about AIO-Studien-gGmbH

How many clinical trials does AIO-Studien-gGmbH have on ClinicalTrials.gov?
AIO-Studien-gGmbH is listed as the lead sponsor on 59 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
How many of AIO-Studien-gGmbH's trials are in Phase 3?
6 of AIO-Studien-gGmbH's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does AIO-Studien-gGmbH focus on?
AIO-Studien-gGmbH's most-studied conditions on ClinicalTrials.gov are Metastatic Colorectal Cancer, Colorectal Neoplasms, Esophageal Cancer, GastroEsophageal Cancer, Biliary Tract Cancer.
When are AIO-Studien-gGmbH's next clinical trial readouts?
AIO-Studien-gGmbH has 3 upcoming primary-completion readouts tracked here; the soonest is “D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer”, expected around 2025-12.